By serving as a dedicated NCORP, the Colorado Cancer Research Program (CCRP) seeks to advance cancer research for patients, local communities, healthcare providers and hospitals in the Western mountain state region. The goal is to provide and maintain access to NCI research and trials focused on cancer control (CC), cancer prevention (CP), cancer disparities, cancer care delivery (CCDR), as well as provide access to NCTN treatment and imaging trials. In the next funding cycle, CCRP has developed strategic partnerships with regionally focused mid-sized Healthcare systems whose organizations have a common ethos of patient- centered high value care and a shared commitment to implementing NCI trials in the community setting. The consortium is diverse in its membership, not only from a regional perspective, but also in regards to the make- up of its providers of healthcare services, ranging from Healthcare Systems, to Independent Hospitals, to private practice physician offices. This diversity of recruitment sites will allow for broader participation in NCORP projects, so as to achieve CCRP?s main goal of providing patients and communities within its catchment area, the opportunity to participate in and potentially benefit from the innovative and scientifically rigorous research projects of the NCI.

Public Health Relevance

The Colorado Cancer Research Program is a cancer clinical trial research organization who seeks to provide access to NCI sponsored clinical trials for our consortium members located in the mountain states of Colorado, Wyoming, Montana, Utah, Washington and Alaska. By partnering with Healthcare systems and community hospitals, we will provide access to innovative therapies and cancer related research projects for patients in their home communities, all the while, pursuing and supporting NCI strategic research priorities. We work with Healthcare systems, Hospitals, Providers and Patients to disseminate knowledge about clinical trial options, clinical trial participation, and clinical trial outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189805-06
Application #
9763372
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Parker, Bernard W
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2019-08-19
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Colorado Cancer Research Program, Inc.
Department
Type
DUNS #
148748325
City
Denver
State
CO
Country
United States
Zip Code
80222
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Marur, Shanthi; Li, Shuli; Cmelak, Anthony J et al. (2017) E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol 35:490-497
Goss, Paul E; Ingle, James N; Pritchard, Kathleen I et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375:209-19
Belani, Chandra P; Dahlberg, Suzanne E; Rudin, Charles M et al. (2016) Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer 122:2371-8
Margolese, Richard G; Cecchini, Reena S; Julian, Thomas B et al. (2016) Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387:849-56
Ganz, Patricia A; Cecchini, Reena S; Julian, Thomas B et al. (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387:857-65
Abraham, Jame; Robidoux, André; Tan, Antoinette R et al. (2015) Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. Breast Cancer Res Treat 152:399-405
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32